Open AccessEffects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Author(s) -
Mihai Gheorghiade,
Wendy A. Gattis,
Christopher M. O'Connor,
Kirkwood F. Adams,
Uri Elkayam,
Alejandro Barbagelata,
Jalal K. Ghali,
Raymond L. Benza,
Frank McGrew,
Marc Klapholz,
John Ouyang,
Cesare Orlandi
Publication year - 2004
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.291.16.1963
Subject(s) - medicine , tolvaptan , heart failure , vasopressin antagonists , ejection fraction , randomization , placebo , interquartile range , randomized controlled trial , cardiology , antagonist , receptor , alternative medicine , pathology
Nearly 1 million hospitalizations for chronic heart failure occur yearly in the United States, with most related to worsening systemic congestion. Diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom